IL-6 Inhibitor Vamikibart Boosts Vision Gains in Diabetic Macular Edema Trial

Diabetic macular edema is a leading cause of vision loss in people with diabetes, driven by both abnormal blood vessel growth and chronic inflammation. Standard treatment targets a protein called VEGF to reduce leaky vessels, but many patients still lose vision. New trial data suggest that also blocking the inflammatory protein IL-6 could meaningfully improve outcomes.

In a randomized trial presented at the Association for Research in Vision and Ophthalmology annual meeting, patients receiving both ranibizumab and the IL-6 inhibitor vamikibart gained an average of 12.8 letters on a standard vision chart over 44 to 48 weeks, compared to 9.4 letters with ranibizumab alone — a 36% greater improvement. Retinal thickness, a key marker of swelling, also decreased more in the combination group. More patients in the combination arm achieved large vision gains and normalization of retinal anatomy.

A companion monotherapy trial confirmed that vamikibart alone improved both vision and retinal thickness independent of VEGF blockade, validating IL-6 as a distinct therapeutic target in DME. This is clinically significant because it means inflammation and angiogenesis are separate, addressable pathways in the disease.

However, the combination therapy was associated with higher rates of intraocular inflammation and elevated eye pressure, raising safety considerations. Researchers also acknowledged that a substantial proportion of patients still did not meet standard response criteria, underscoring that DME is a heterogeneous disease unlikely to be solved by any single mechanism.

Looking ahead, a phase I trial is underway testing a bispecific antibody that targets both VEGF and IL-6 in a single injection. Experts emphasized the need for biomarkers to identify which patients have IL-6-driven inflammation, enabling more personalized treatment. These findings represent a meaningful step toward precision medicine for diabetic eye disease.